02 February 2024
02 February 2024
The T cell therapy BST02 utilises adoptive immune cell therapy technology, expanding the patient's own tumour-infiltrating lymphocytes.
Merck & Co (MSD) has reported a 1% revenue increase from 2022, and may face setbacks in the next few years from top-selling drugs.
The company is also preparing to file an investigational new drug application in the second half of 2024.
GlobalData reports that healthcare providers (HCPs) predict a continued increase in drug prices, as inflationary pressures rise.
The collaboration grants Sanofi the right of initial negotiation to license compounds for conditions such as immunological and metabolic syndrome indications.
The latest $3m investment brings the funds raised by the company to $40m.
The financing extension brings Series B total funding to $39.5m, helping advance the UK company’s lead DNA MMR protein candidate.
The French Government grant will cover preclinical and clinical research for Vivet’s gene therapy for cerebrotendinous xanthomatosis.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
